Labcorp’s AI real‑world data platform

Labcorp said on April 14 it launched an artificial intelligence platform with Amazon Web Services and Datavant to help drugmakers analyze Alzheimer’s disease data faster. (labcorp.com) The platform is built around “real-world data,” a term the Food and Drug Administration uses for information routinely collected during care, including electronic health records, claims, registries and lab results. Labcorp said its system gives researchers access to longitudinal laboratory data and analytics tools aimed at Alzheimer’s studies. (fda.gov) (labcorp.com) Labcorp said the product uses “agentic” artificial intelligence, meaning software agents can carry out multistep tasks such as finding relevant datasets, preparing analyses and generating outputs with less manual work. The company said the first use case is Alzheimer’s disease, where researchers often need to combine data from many sources over long periods. (labcorp.com 1) (labcorp.com 2) In plain terms, this kind of system works like a search-and-analysis layer on top of scattered medical records: it links datasets, standardizes them and lets researchers ask narrower questions about patients, treatments and outcomes. Datavant’s business centers on connecting health data across organizations while keeping records privacy-protected, and Amazon Web Services has been pitching cloud tools for real-world evidence work in life sciences. (datavant.com) (aws.amazon.com) Drug companies have been pushing harder into real-world evidence because regulators already use it in some decisions, especially for post-approval studies and added indications for approved products. The Food and Drug Administration’s Advancing Real-World Evidence Program was created to improve the quality and acceptability of those approaches. (fda.gov 1) (fda.gov 2) Alzheimer’s research is a natural target because the disease progresses over years, diagnosis can be delayed and trial recruitment depends on finding the right patients at the right stage. A platform that can sift linked records, lab histories and other routine care data could help sponsors design studies and identify patient cohorts faster. (labcorp.com) (fda.gov) The announcement also fits a broader market pattern: data companies are trying to package access, linkage and analysis into one product instead of selling each piece separately. Datavant said in 2025 that it planned to acquire Aetion, a real-world evidence platform, to expand those capabilities across the clinical and commercial drug-development process. (biospace.com) For now, Labcorp is framing the new platform around one disease area and one promise: less time spent assembling data, more time spent testing drug-development questions. Whether that translates into faster Alzheimer’s studies will depend on how well sponsors and regulators accept the evidence it produces. (labcorp.com) (fda.gov)